The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Pharmacodynamic (PD) evaluation of soluble proteins from a phase I trial of lapatinib (L) in combination with sorafenib (S).
Matteo Simonelli
No relevant relationships to disclose
Paolo Andrea Zucali
No relevant relationships to disclose
Elena Lorenzi
No relevant relationships to disclose
Luca Rubino
No relevant relationships to disclose
Fabio De Vincenzo
No relevant relationships to disclose
Matteo Perrino
No relevant relationships to disclose
Lorenza Rimassa
No relevant relationships to disclose
Laura Giordano
No relevant relationships to disclose
Armando Santoro
No relevant relationships to disclose